Blue Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,029
Closed -$58.9K – 2554
2026
Q2
$58.9K Hold
1,029
– – ﹤0.01% 1282
2026
Q1
$58.1K Hold
1,029
– – ﹤0.01% 1258
2025
Q4
$61.2K Sell
1,029
-27
-3% -$1.47K ﹤0.01% 1277
2025
Q3
$57.2K Buy
1,056
+27
+3% +$1.54K ﹤0.01% 1351
2025
Q2
$56.6K Buy
1,029
+41
+4% +$2.41K ﹤0.01% 1379
2025
Q1
$69.8K Buy
988
+21
+2% +$1.41K ﹤0.01% 1165
2024
Q4
$63.6K Buy
967
+108
+13% +$7.23K ﹤0.01% 1139
2024
Q3
$70.7K Buy
859
+717
+505% +$59.9K ﹤0.01% 1413
2024
Q2
$12.4K Buy
+142
New +$11.8K ﹤0.01% 1856
2024
Q1
– Sell
-44
Closed -$4K – 2231
2023
Q4
$4K Buy
44
+3
+7% +$265 ﹤0.01% 1896
2023
Q3
$4K Sell
41
-1
-2% -$89 ﹤0.01% 1679
2023
Q2
$4K Sell
42
-5
-11% -$471 ﹤0.01% 1572
2023
Q1
$5K Buy
47
+41
+683% +$4.25K ﹤0.01% 1772
2022
Q4
$1K Buy
+6
New +$563 ﹤0.01% 2015

Other funds holding BMRN

Blue Trust's BMRN Position: Q3 2026 in Review

Blue Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2026, closing a stake of 1,029 shares — an estimated $58.9K sold.

Blue Trust first reported a position in BMRN in Q4 2022 and held it in 14 quarters. The position peaked at $70.7K in Q3 2024. 443 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Blue Trust reported no remaining BioMarin Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Blue Trust sold 1,029 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $58.9K.
  • Blue Trust first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 14 quarters.
  • Blue Trust's BioMarin Pharmaceuticals position peaked at $70.7K in Q3 2024.
  • 443 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.